XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 54.56

Change

+0.27 (+0.50)%

Market Cap

USD 0.85B

Volume

40.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.15 (-0.58%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.08 (-0.17%)

USD 115.48B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.05 (-0.10%)

USD 95.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 88.54B
FRCJ:F UBS MSCI Japan Socially Respon..

-0.03 (-0.14%)

USD 75.49B
EUNL:F iShares Core MSCI World UCITS ..

+0.31 (+0.33%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.05 (+0.02%)

USD 56.16B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.03 (-0.23%)

USD 56.02B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.17 (-0.17%)

USD 51.63B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.76% 69% C- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.76% 66% D+ 60% D-
Trailing 12 Months  
Capital Gain 12.03% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.03% 63% D 60% D-
Trailing 5 Years  
Capital Gain 69.57% 83% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.57% 83% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 10.62% 81% B- 75% C
Dividend Return 10.62% 79% B- 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 60% D- 83% B
Risk Adjusted Return 99.45% 98% N/A 96% N/A
Market Capitalization 0.85B 71% C- 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike